Eating disorders

Psychiatric Drugs in Children and Adolescents: Basic Pharmacology and Practical Applications

Volumn 9783709115015, Issue , 2014, Pages 429-437

  Herpertz Dahlmann, Beate ^a   Wewetzer, Christoph ^b  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b KLINIKEN DER STADT KÖLN GGMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930884977     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-7091-1501-5_16     Document Type: Chapter

References (46)

1. Alvarez PA, Pahissa J (2010) QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 5:97-104
2. American Psychiatric Association (2006) Practice guideline for the treatment of patients with eating disorders, 3rd edn. http://psychiatryonline.org/content.aspx?bookid=28§ionid=1671334
3. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn (DSM-5 TM ). American Psychiatric Publishing, Washington/ London
4. Attia E, Haiman C, Walsh BT, Flater SR (1998) Doesfluoxetine augment the inpatient treatment of anorexia nervosa? Am J Psychiatry 155:548-551
5. Bacaltchuk J, Hay P, Mari JJ (2000) Antidepressants versus placebo for the treatment of bulimia nervosa: A systematic review. Aust N Z J Psychiatry 34:310-317
6. Barbarich NC, McConaha CW, Gaskill J, La Via M, Frank GK, Achenbach S, Plotnicov KH, Kaye WH (2004) An open trial of olanzapine in anorexia nervosa. J Clin Psychiatry 65:1480-1482
7. Biedermann J, Herzog DB, Rivinus TM (1985) Amitriptyline in the treatment of anorexia nervosa: A double-blind placebo-controlled study. J Clin Psychopharmacol 5:10-16
8. Birmingham CL, Goldner EM, Bakan R (1993) Controlled trial of zinc supplementation in anorexia nervosa. Int J Eat Disord 15:251-255
9. Bissada H, Tasca GA, Barber AM, Bradwejn J (2008) Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebo-controlled trial. Am J Psychiatry 165:1281-1288
10. Brambilla F, Garcia CS, Fassino S, Daga AG, Favaro A, Santonastaso P, Ramaciotti C, Bondi E, Mellado C, Borriello R, Monteleone P (2007) Olanzapine therapy in anorexia nervosa: psychobiological effects. Int Clin Psychopharmacol 22:197-204
11. Casper RC, Schlemmer RF, Javaid JI (1987) A placebocontrolled crossover study of oral clonidine in acute anorexia nervosa. Psychiatry Res 20:249-260
12. Chen Y, Silverstone T (1990) Lithium and weight gain. Int Clin Psychopharmacol 5:217-225
13. Corwin J, Connelly S, Paz S, Schwartz M, Wirth JA (1995) Chart review of rate of weight-gain in eating disorder patients treated with tricyclic antidepressants orfluoxetine. Prog Neuropsychopharmacol Biol Psychiatry 19:223-228
14. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Henninger GR, Charney DS (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine orfluoxetine: implications for the role of serotonin n the mechanism of antidepressant action. Biol Psychiatry 15:212-220
15. Fazeli PK, Calder GL, Miller KK, Miskra M, Lawson EA, Meenaghan E, Lee H, Herzog D, Klibanski A (2012) Psychotropic medication use in anorexia nervosa between 1997 and 2009. Int J Eat Disord 45:970-976
16. Ferguson CP, La Via MC, Crossan MP, Kaye WH (1999) Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 25:11-17
17. Fichter M, Kruger R, Rief W, Holland R, Döhne J (1996) Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology. J Clin Psychopharmacol 16:9-18
18. Fluoxetine Bulimia Nervosa Collaborative Study Group (1992) Fluoxetine in the treatment of bulimia nervosa: A multicenter, placebo-controlled, double-blind trial. Arch Gen Psychiatry 49:139-147
19. Gross HA, Ebert MH, Faden VB (1981) A double-blind controlled trial of lithium carbonate in primary anorexia nervosa. J Psychopharmacol 3:165-171
20. Hagman J, Gralla J, Sigel E, Ellert S, Dodge M, Gardner R, O'Lonergan T, Frank G, Wamboldt MZ (2011) A double-blind, placebo-controlled study of risperidone for the treatment of adolescents and young adults with anorexia nervosa: A pilot study. J Am Acad Child Psychiatry 50:915-924
21. Halmi KA, Eckert ED, LaDu TJ, Cohen J (1986) Anorexia nervosa: treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry 43:177-181
22. Heer M, Mika C, Grzella I, Heussen N, Herpertz-Dahlmann B (2004) Bone turnover during inpatient nutritional therapy and outpatient follow-up in patients with anorexia nervosa compared with that in healthy control subjects. Am J Clin Nutr 80:774-781
23. Herpertz S, Herpertz-Dahlmann B, Fichter M, Tuschen-Caffier B, Zeeck A (eds) (2011) S3-Leitlinie Diagnostik und Behandlung der Essstörungen. Springer, Berlin
24. Herpertz-Dahlmann B, Salbach-Andrae H (2009) Overview of treatment modalities in adolescent anorexia nervosa. Child Adolesc Psychiatr Clin N Am 18:131-145
25. Hillebrand JJ, van Elburg AA, Kas MJ, van Engeland H, Adan RA (2005) Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa? Biol Psychiatry 58:165-171
26. Holtkamp K, Konrad K, Kaiser N, Ploennes Y, Heussen N, Grzella I, Herpertz-Dahlmann B (2005) A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. J Psychiatr Res 39:303-310
27. Kafantaris V, Leigh E, Hertz S, Berest A, Schebendach J, Sterling WM, Saito E, Sunday S, Higdon C, Golden NH, Malhotra AK (2011) A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol 21:207-212
28. Kaye WH, Nagata T, Weltzin TE, Hsu LK, Sokol MS, McConaha C, Plotnicov KH, Weise J, Deep D (2001) Double-blind placebo-controlled administration offluoxetine in restricting-and restricting-purging-type anorexia nervosa. Biol Psychiatry 49:644-652
29. Keys A, Brozek J, Henschel A, Mickelsen O, Taylor HL (1950) The biology of human starvation. University of Minneapolis Press, Minneapolis
30. Kotler LA, Devlin MJ, Walsh BT (2002) Eating disorders and related disturbances. In: Kutcher S (ed) Practical child and adolescent psychopharmacology. Cambridge University Press, Cambridge, pp 410-430
31. Lask B, Fosson A, Rolfe U, Thomas S (1993) Zinc defi-ciency and childhood-onset anorexia nervosa. J Clin Psychiatry 54:63-66
32. Lebow J, Sim LA, Erwin PJ, Murad MH (2013) The effect of atypical antipsychotic medications in individuals with anorexia nervosa: A systematic review and metaanalysis. Int J Eat Disord 46:332-339
33. Mehler C, Wewetzer C, Schulze U, Theisen F, Dittmann RW, Warnke A (2001) Olanzapine in children and adolescents with chronic anorexia nervosa. A study offive cases. Eur Child Adolesc Psychiatry 10: 151-157
34. Misra M, Katzman D, Miller KK, Mendes N, Snelgrove D, Russell M, Goldstein MA, Ebrahimi S, Clauss L, Weigel T, Mickley D, Schoenfeld DA, Herzog DB, Klibanski A (2011) Physiologic estrogen replacement increases bone density in adolescent girls with anorexia nervosa. J Bone Miner Res 26: 2430-2438
35. Mitchell JE, Raymond N, Specke S (1993) A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. Int J Eat Disord 14:229-247
36. Mitchell JE, Peterson CB, Myers T, Wonderlich S (2001) Combining pharmaco therapy and psychotherapy in the treatment of patients with eating disorders. Psychiatr Clin North Am 24:315-323
37. National Institute for Clinical Excellence ("NICE") (2004) Eating disorders: core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. National Institute for Clinical Excellence, London, www.nice.org.uk
38. Powers PS, Bruty H (2009) Pharmacotherapy for eating disorders and obesity. Child Adolesc Psychiatr Clin N Am 18:175-187
39. Powers PS, Santana CA, Bannon YS (2002) Olanzapine in the treatment of anorexia nervosa: an open label trial. Int J Eat Disord 32:146-154
40. Romano SJ, Halmi KA, Sarkar NP, Koke SC, Lee JS (2002) A placebo-controlled study offluoxetine in continued treatment of bulimia nervosa after successful acutefluoxetine treatment. Am J Psychiatry 159:96-102
41. Vandereycken W (1984) Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. Br J Psychiatry 144:288-292
42. Vandereycken W, Pierloot R (1982) Pimozide combined with behaviour therapy in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 66:445-450
43. Walsh BT, Develin MJ (1992) The pharmacologic treatment of eating disorders. Psychiatr Clin North Am 15:149-160
44. Walsh BT, Wilson GT, Loeb KL (1997) Medication and psychotherapy in the treatment of bulimia nervosa. Am J Psychiatry 154:523-531
45. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, Rockert W (2006) Fluoxetine after weight restoration in anorexia nervosa: A randomized controlled trial. JAMA 295:2605-2612
46. World Health Organisation (1996) Multiaxial classification of child and adolescent psychiatric disorders. The ICD-10 classification of mental and behavioral disorders in children and adolescents. Cambridge University Press, Cambridge